All In Biotech

Free tool

Medicare drug spending

CMS's Spending by Drug data: what Medicare paid for each drug before manufacturer rebates. Part D covers drugs dispensed by pharmacies; Part B covers drugs given in a doctor's office or hospital outpatient department. Commercial and list prices are not public data and are not shown.

Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations

Part D, 2024

$288.7B

Gross drug spending in the dataset

Part B, 2024

$60.8B

Gross drug spending in the dataset

Drugs listed

6

Part D and Part B

Total spending by year

  • Part D
  • Part B
View as table
YearPart DPart B
2020$194,092,038,339$37,778,829,680
2021$213,513,349,361$40,135,340,775
2022$239,779,215,689$44,241,259,745
2023$275,808,918,753$50,775,853,083
2024$288,667,842,058$60,838,164,403
Reset

Top 6 by total spending

2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.

DrugPartSpendingChangeBeneficiariesPer beneficiaryPer unit
Humira(Cf) Pen

Adalimumab

D$4.33B-2%63,768$67,882$3,531.42
Humira Pen

Adalimumab

D$697M-16%11,719$59,511$3,351.33
Humira(Cf)

Adalimumab

D$401M-10%6,661$60,186$3,407.72
Humira

Adalimumab

D$209M-19%3,912$53,401$3,377.97
Humira(Cf) Pen Crohn'S-Uc-Hs

Adalimumab

D$59.2M-16%2,792$21,209$6,829.98
Humira(Cf) Pen Psor-Uv-Adol Hs

Adalimumab

D$20.7M-16%1,497$13,853$4,536.74

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.